Brief: Inhibikase Therapeutics Reports 2022 Loss Per Share Of $0.72
31/03/2023 13:25
March 31 (Reuters) - Inhibikase Therapeutics Inc
IKT.O :
* INHIBIKASE THERAPEUTICS REPORTS FULL YEAR 2022 FINANCIAL
RESULTS
AND HIGHLIGHTS RECENT PERIOD ACTIVITY
* INHIBIKASE THERAPEUTICS INC - FY LOSS PER SHARE $0.72
* INHIBIKASE THERAPEUTICS INC - EXPECTS THAT EXISTING CASH
AND
CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND OPERATIONS INTO Q4
OF 2024
Source text for Eikon: ID:nPn3YL97Za
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share